Thane Wettig
Vermögen: 204 190 $ am 30.06.2026
Vermögen: 204 190 $ am 30.06.2026
Thane Wettig is Chief Executive Officer & Director at Kyntra Bio, Inc. since 2023.
Former roles include Chief Commercial Officer at Intarcia Therapeutics, Inc. and Vice President-Diabetes Brands Global Marketing at Lilly Diabetes from 2004 to 2009.
Education includes undergraduate and MBA degrees from Washington University in St. Louis.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
KYNTRA BIO, INC. 0.67% | 06.06.2026 | 27’045 ( 0.67% ) | 204 190 $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KYNTRA BIO, INC. | Vorstandsvorsitzender | 23.07.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
Lilly Diabetes | Corporate Officer/Principal | 01.01.2009 |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 4 |
|---|---|
Washington University in St. Louis
Washington University in St. Louis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
FibroGen, Inc.
FibroGen, Inc. Pharmaceuticals: MajorHealth Technology Develops biotechnology-based drugs | Health Technology |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops innovative therapies utilizing the Medici drug delivery system | Health Technology |
Lilly Diabetes |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen